• Recruiting

NCT03562169: Phase 3: Ixazomib in Autologous Stem Cell Transplant in RRMM Myeloma XII (ACCoRd)

Updated: Oct 4

NCT03562169: Phase 3: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

Myeloma XII (ACCoRd)

NCT03562169: Phase 3: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)


Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). The primary objectives of this study are to determine:

The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor

The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS)


Sponsor

University of Leeds


Collaborators

Cancer Research UK

Takeda

 

ClinicalTrials.gov Identifier: NCT03562169

Official Title: A Phase III Study to Determine the Role of Ixazomib as an Augmented Conditioning Therapy in Salvage Autologous Stem Cell Transplant (ASCT) and as a Post-ASCT Consolidation and Maintenance Strategy in Patients With Relapsed Multiple Myeloma

First Posted : June 19, 2018

Click here for details on ClinicalTrials.gov


A trial looking at ixazomib for people with myeloma that has come back (Myeloma XII ACCoRd) | Cancer Research UK

 

Ixazomib: National Cancer Institute

Ixazomib: MedlinePlus Drug Information

 

Drug: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction

Drug: Conventional autologous stem cell transplant (ASCT-con)

Drug: Augmented autologous stem cell transplant (ASCT-aug)

Drug: ITD consolidation and ixazomib maintenance vs. No further therapy

 

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Trials;2018 Mar

Click here for details

 

Locations

United Kingdom

 

RELATED POSTS

MCT: MYELOMA CLINICAL TRIALS WITH IXAZOMIB


NCT02312258: TOURMALINE-MM4 - Phase 3: A Study of Oral Ixazomib Maintenance Therapy in Participants With NDMM-TIE

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Click here for details


NCT02181413: TOURMALINE-MM3 - Phase 3 - Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

Click here for details


NCT01850524: TOURMALINE-MM2 - Phase 3 - Comparing Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Click here for details


NCT01564537: TOURMALINE-MM1 - Phase 3 - Comparing Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex RRMM

A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Click here for details


NCT03941860: EAA171 - OPTIMUM - Phase 3 - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma

Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM)

Click here for details


NCT03720041: Myeloma XIV - (FiTNEss) - Phase 3: Frailty-adjusted Therapy in Transplant Non-Elig. NDMM

Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)

Click here for details


NCT03651128: (KarMMa-3) - Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma RRMM

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Click here for details


NCT02406144: GEM2014MAIN - Phase 3 - Maintenance Lenalidomide, Dex VS Lenalidomide, Dex. & MLN9708 After ASCT NDMM

Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma

Click here for details


NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM

Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma

Click here for details


NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib RRMM

Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma

Click here for details







Posts Archive